U.S. Food and Drug Administration (FDA) has approved carotid stent for the treatment of patients with carotid artery disease. The stent will be manufactured by Boston Scientific Cardiovascular Business.

Hank Kucheman, Senior Vice President and Group President of Boston Scientific's Cardiovascular business said,"We are pleased to bring this proven technology to physicians in the United States.Excellent patient outcomes and ease of use in complex anatomy have already made this system the number-one stenting option for treating carotid artery disease in Europe and other countries outside the U.S. It offers a less-invasive alternative to surgery for treating carotid artery disease, and can help reduce the risk of stroke, which can have devastating effects."

The Carotid WALLSTENT is a self-expanding and is mounted on a rapid exchange delivery system. The stent is so designed that it would re-open the carotid artery by treating stenoses and improving blood flow to the brain. It has a closed-cell design, which will help in excellent lesion coverage and angiographic results. Its design is considered to be highly deliverable and provide access to the toughest lesions.